SEHK:9926Biotechs
Akeso (SEHK:9926) Dosed Its First AK138D1 Patient, Is The 47% Undervalued View Too Bullish?
Akeso (SEHK:9926) is back in focus after dosing the first patient in a Phase Ib/II trial of its HER3 antibody drug conjugate AK138D1 for advanced non small cell lung cancer.
See our latest analysis for Akeso.
Akeso’s latest trial milestone comes after a period where sentiment has cooled, with the share price at HK$91.95 and the 1-year total shareholder return down 39.55%, although the 3-year total shareholder return remains very strong.
If Akeso’s oncology work has caught your attention, this...